Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma

Core Viewpoint - Theralase Technologies Inc. has demonstrated that its lead compound Rutherrin®, when combined with Metformin and radiation, effectively destroys Non-Hodgkin's Lymphoma (NHL) in an animal model, indicating potential for improved cancer treatment options [1][2][3]. Company Overview - Theralase Technologies Inc. is a clinical stage pharmaceutical company focused on the research and development of light, radiation, sound, and drug-activated small molecules for the treatment of various cancers, bacteria, and viruses [1][8]. - Rutherrin® is currently under development for intravenous administration to treat multiple cancers, including brain, lung, pancreatic, and muscle invasive bladder cancer [2][8]. Industry Context - Non-Hodgkin's Lymphoma is ranked as the 5th to 9th most common cancer globally, with an estimated 544,000 new cases and 260,000 deaths in 2020 [2]. - The global market for NHL is projected to reach $16.5 billion by 2031, highlighting significant commercial potential for effective treatments [2][8]. Research Findings - In a study, mice inoculated with A20 mouse lymphoma cells were treated with Rutherrin®, Metformin, and radiation over three weeks, leading to significant tumor destruction and improved survival rates [3][7]. - The combination of Rutherrin®, Metformin, and radiation resulted in the best overall response, including one case of complete tumor regression [5][7]. - Future studies will explore the effectiveness of this trimodal therapy on various cancerous tumors, potentially leading to novel therapeutic options [7].